GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2008

Warnex Gains Rights from Xenomics to Develop AML Assay

  • Xenomics granted Warnex Medical Laboratories a nonexclusive license in Canada to offer NPM1 testing as a laboratory service for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).

    Xenomics holds exclusive rights to a discovery that showed that many AML patients have mutations in the NPM1 gene, which can be used as a favorable marker for clinical outcome.

    Warnix will use the license in diagnostic applications such as patient stratification during clinical trials. The test may also help physicians with prognosis and monitoring patients for residual disease during chemotherapy.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?